FDA 483 - Catalent CTS, LLC - October 23, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Catalent CTS, LLC in Kansas City, MO, a drug manufacturer, was inspected by the FDA from October 15-23, 2018. The inspection revealed significant deficiencies in quality control, data integrity, and facility design, particularly concerning the manufacturing process and record-keeping for Selinexor 20mg tablets. Issues included inadequate investigation of discrepancies, insufficient computer system controls, and poor material flow design leading to potential contamination risks.
ID · f0a4108f-c156-48cd-b380-4e63978fb25b